TraceLink unveils industry’s first Compliance and Digital Information Platform for pharmacies with EU FMD requirements
Application "addresses a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients."
TraceLink has unveiled an industry first: an integrated Compliance and Digital Information Platform for pharmacies with EU Falsified Medicines Directive (FMD) requirements.
The new mobile and web-based application enables any pharmacy in the EU to easily comply with verification and decommissioning requirements under the FMD while simultaneously delivering a real-time dashboard for business insights on medicine scans, expiry dates, dispensation trends, product inventory and more. The new platform was revealed at NEXUS 17 in Barcelona during the opening keynote session by TraceLink president and CEO, Shabbir Dahod.
The new Pharmacy Compliance and Digital Information Platform provides a single destination for pharmacies to meet their EU FMD requirements, which take effect in February 2019. Pharmacists who use the application will also benefit from user-friendly dashboard analytics that provide valuable insights from all transaction information that is captured within the application.
Pharmacists can also “opt in” to a service within the app that links them to participating pharmaceutical manufacturers, paving the way for a new digital communication channel designed to enhance the information-sharing between pharmaceutical companies and the healthcare providers who dispense their medications. Once they opt in, pharmacists will be able to receive specific and contextual pharmaceutical product information directly from the manufacturer – including details about indications, usage, best practices for product administration, and potential warnings and precautions - empowering them to deliver a more engaging and informative consultation as they dispense medicines to patients.
“TraceLink has broken new ground with this application, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients,” said Dahod. “Our unique approach of connecting the entire pharmaceutical supply chain on an interoperable network makes TraceLink the only company capable of offering this type of solution and facilitating a new era of real-time information sharing that will transform how the industry provides care to patients. This is the first in a series of steps we are taking to augment our effort of eliminating counterfeit drugs from the global marketplace with applications that deliver tangible and meaningful value to an industry that serves hundreds of millions of people who depend on prescription medications to improve their health.”
TraceLink’s new Pharmacy Compliance and Digital Information Platform merges EU FMD compliance capabilities with real-time insights into pharmaceutical products, offering EU pharmacists the ability to
All services within the Pharmacy Compliance and Digital Information Platform will be provided by TraceLink via its secure Life Sciences Cloud where pharmacists can be assured of the confidentiality and anonymous nature of their dispensing information.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.